S&P 500   3,383.11 (+1.48%)
DOW   27,974.94 (+1.04%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
S&P 500   3,383.11 (+1.48%)
DOW   27,974.94 (+1.04%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
S&P 500   3,383.11 (+1.48%)
DOW   27,974.94 (+1.04%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
S&P 500   3,383.11 (+1.48%)
DOW   27,974.94 (+1.04%)
QQQ   272.44 (+2.73%)
AAPL   452.45 (+3.42%)
MSFT   209.95 (+3.23%)
FB   261.47 (+2.08%)
GOOGL   1,509.17 (+1.93%)
AMZN   3,164.26 (+2.71%)
NVDA   457.48 (+5.41%)
CGC   17.27 (+1.89%)
BABA   255.54 (+2.87%)
TSLA   1,566.14 (+13.95%)
GE   6.63 (-1.49%)
MU   48.57 (+1.70%)
AMD   82.16 (+6.87%)
T   30.21 (+0.03%)
F   7.09 (-1.94%)
ACB   9.81 (-2.10%)
GILD   68.90 (+1.17%)
NFLX   479.55 (+2.70%)
DIS   131.73 (+0.95%)
BAC   26.76 (-0.59%)
BA   175.53 (-2.55%)
Log in

NASDAQ:ICCCImmuCell Stock Price, Forecast & News

$5.69
-0.10 (-1.73 %)
(As of 08/12/2020 02:48 PM ET)
Add
Compare
Today's Range
$5.69
Now: $5.69
$5.69
50-Day Range
$4.44
MA: $5.40
$6.16
52-Week Range
$3.70
Now: $5.69
$8.13
Volume100 shs
Average Volume18,001 shs
Market Capitalization$41.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.72 million
Cash Flow$0.14 per share
Book Value$4.02 per share

Profitability

Net Income$-1,300,000.00

Miscellaneous

Employees47
Market Cap$41.02 million
Next Earnings Date8/12/2020 (Confirmed)
OptionableNot Optionable
$5.69
-0.10 (-1.73 %)
(As of 08/12/2020 02:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

How has ImmuCell's stock been impacted by COVID-19 (Coronavirus)?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ICCC stock has increased by 32.3% and is now trading at $5.69.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of ImmuCell?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ImmuCell
.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for ImmuCell
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) announced its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. The biotechnology company had revenue of $4.91 million for the quarter. ImmuCell had a negative net margin of 10.98% and a negative return on equity of 5.35%.
View ImmuCell's earnings history
.

What price target have analysts set for ICCC?

1 brokers have issued 12 month price targets for ImmuCell's shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate ImmuCell's share price to reach $14.00 in the next year. This suggests a possible upside of 146.0% from the stock's current price.
View analysts' price targets for ImmuCell
.

Has ImmuCell been receiving favorable news coverage?

Press coverage about ICCC stock has been trending negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmuCell earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about ImmuCell
.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 24,000 shares, an increase of 410.6% from the January 31st total of 4,700 shares. Based on an average daily trading volume, of 75,400 shares, the short-interest ratio is currently 0.3 days. Currently, 0.5% of the shares of the company are short sold.
View ImmuCell's Short Interest
.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Biocept (BIOC), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Novavax (NVAX), Verastem (VSTM) and Vaxart (VXRT).

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by many different retail and institutional investors. Top institutional shareholders include Flagship Harbor Advisors LLC (0.17%) and Ingalls & Snyder LLC (0.14%). Company insiders that own ImmuCell stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends for ImmuCell
.

Which major investors are selling ImmuCell stock?

ICCC stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC.
View insider buying and selling activity for ImmuCell
.

Which major investors are buying ImmuCell stock?

ICCC stock was bought by a variety of institutional investors in the last quarter, including Flagship Harbor Advisors LLC. Company insiders that have bought ImmuCell stock in the last two years include David Cunningham, and David Scott Tomsche.
View insider buying and selling activity for ImmuCell
.

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.69.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $41.02 million and generates $13.72 million in revenue each year. The biotechnology company earns $-1,300,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. ImmuCell employs 47 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.